Kenvue Inc.

The filings describe a company whose reported profit has recovered faster than its sales. Across its three reportable segments, Self Care, Skin Health and Beauty, and Essential Health, the MD&A lists brands such as Tylenol, Zyrtec, Neutrogena, Aveeno, Listerine, and Johnson's. Full-year 2025 operating income of $2.41 billion was above the 2024 level of $1.84 billion but below the $2.51 billion reported for 2023 and the $2.92 billion for 2022, so the recovery is partial across the years shown. Year-end 2025 balance sheet figures show assets of $27.08 billion, liabilities of $16.31 billion, and equity of $10.77 billion, with assets up from $25.6 billion at the end of 2024. Because the company is party to a pending transaction with a mix of stock and cash consideration, its standalone trajectory may be less informative than it would otherwise be, and readers may want to look at the Merger Agreement terms and the closing conditions described in the MD&A. The risk factors describe acetaminophen and talc litigation and note the rebranding efforts tied to the Separation from Johnson & Johnson. No forensic scores are on file for this synthesis, so no Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index result is reported here, and no score can be inferred from the figures shown. Readers may want to compare the filed numbers against the legal proceedings disclosure in the 10-K and the restructuring note in the 10-Q when reviewing the company.

Catalyst.The MD&A points to the pending combination with Kimberly-Clark as the central event. Kenvue shareholders would receive 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash per share, and Kenvue holders are expected to own about 46% of the combined company. The merger is expected to close in the second half of 2026, subject to U.S. antitrust clearance and foreign regulatory approvals. Operating results are improving: for the fiscal three months ended March 29, 2026, net sales rose 4.5% to $3,909 million and operating income rose 37.5% to $767 million, while selling, general, and administrative expenses fell 5.5% to $1,453 million. The company also cited a February 2026 restructuring initiative aimed at optimizing its operating model and supply chain.

Hidden risk.The gap between profit and sales is easy to miss. Full-year 2025 net income of $1.47 billion was up from $1.03 billion in 2024, yet revenue fell from $15.46 billion to $15.12 billion, a decline of about 2.2%. The risk factors name acetaminophen and talc litigation as legal matters whose outcome is uncertain, and they also cite substantial indebtedness, the need to maintain credit ratings, and the continued use of the legacy Johnson's brand. The filing estimates gross tariff exposure of approximately $90 million annualized, and the amount and timing of any refunds following the February 2026 Supreme Court ruling on IEEPA tariffs remain uncertain. If the merger does not complete, these standalone risks remain with Kenvue.